EUCTR2014-000848-14-FR进行中(未招募)1 期
Endothelin and Ischemic optic Neuropathy study group - Endothelin and Ischemic Optic Neuropathy study group
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Men(People) or women of more than 50 years,
- •Negative pregnancy test and use of an effective not hormonal contraception during all the duration of the study for the not menopausal women OR(WHERE) the menopause
- •Patients having signed the form of consent,
- •Patients affiliated to a national insurance scheme or a beneficiary of such a diet(regime).
- •The diagnosis of NOIAA is put in front of the recent appearance (lower in 21 days) a change of the field of vision, associated or not with a reduction in quickly progressive or rough painless visual acuteness and/or
- •AND associated with the clinical examination in an oedema papillaire diffuse or sectorial, of pale / white color, sometimes with péripapillaires bleedings.
- •The diagnosis of disease of Horton must be eliminated (cf page 22)
- •The diagnosis of a syndrome of apnea of the obstructive sleep (index of apneas-hypopnées = the 15 / hour of recording) is not essential for the randomization. Given that the not expanding(carrier) patients of a SAS(AIRLOCK,SIEVE) represent 15 % of the population studied NOIAA, an analysis a posteriori of these patients will be realized.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 43
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 43
排除标准
- •Cannot be included the subjects answering in at least one of the following criteria:
- •Pregnant woman, parturiente or nursing mother
- •Women old enough to procreate using a hormonal alone contraception, about is its mode of administration.
- •Signs which can make suspect another inflammatory neuropathy: NOIAA artéritique (disease of Horton), pain during the mobilization of the globe or any sign which can evoke an optical névrite, a diagnosis known for SEP(MULTIPLE SCLEROSIS), history of inflammatory optical neuropathy (gay or ipsi-side). A biopsy of the temporal artery will be realized if symptoms evoking Horton, or pale and/or diffuse oedema, or franking(obliteration) of the central artery of the associated retina.
- •Signs which can evoke a retinal pathology,
- •Signs which can evoke a neuroretinitis or another optical neuropathy. Any atypie will require the realization of a brain imaging (MRI)
- •Patients reached(affected) by another eye pathology intercurrente acute(sharp) or chronic interfering on the visual acuteness or the field of vision (rétinopathie diabetic, medicinal or other, other optical neuropathy pressure of which close(plain) glaucoma or controlatéral and/or intraoculaire > 30 mmHg, cataract(waterfall) advance(overhang), corneal opacities, amblyopia 5/10, strong nearsightedness > 6 dioptres)
- •Simultaneous bilateral NOIAA, spaced out of 1 month or less
研究者
相似试验
已完成
1 期
Effects of Non-Specific Endothelin-A Receptor Blockade on Ocular Blood Flow in Patients With GlaucomaGlaucomaBlood Flow VelocityNCT00701597Medical University of Vienna28
已完成
不适用
Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist TherapyGlaucomaPulmonary HypertensionNCT00452283University of Colorado, Denver23
招募中
2 期
A Study to Assess the Effects of the Endothelin Receptor Antagonist Zibotentan and the SGLT2 Inhibitor Dapagliflozin in Patients elevated Albuminuria: a Randomized Double Blind Cross-Over Trialdiabetic kidney disease1001265310029149diabetic nephropathyNL-OMON54022niversitair Medisch Centrum Groningen12
进行中(未招募)
1 期
A Study to Assess the Effects of the drugs Zibotentan and Dapagliflozin in Patients with Elevated Levels of Protein in UrinePatients with elevated AlbuminuriaMedDRA version: 21.1Level: PTClassification code 10061835Term: Diabetic nephropathySystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.0Level: PTClassification code 10016807Term: Fluid retentionSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2021-001324-18-NLniversity Medical Center Groningen38
招募中
1 期
A Study to Assess the Effects of the drugs Zibotentan and Dapagliflozin in Patients with Type 2 Diabetes and Elevated Levels of Protein in UrinePatients with Type 2 Diabetes and elevated AlbuminuriaMedDRA version: 21.1Level: PTClassification code 10061835Term: Diabetic nephropathySystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.0Level: PTClassification code 10016807Term: Fluid retentionSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2021-001324-18-DKniversity Medical Center Groningen36
